Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver Cancer

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Aug. 16, 2024 -- For patients with hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) use prior to liver transplant (LT) does not worsen outcomes, according to research published online July 10 in the Journal of Hepatology.

Mohammad Saeid Rezaee-Zavareh, from the Middle East Liver Diseases Center in Tehran, Iran, and colleagues summarized the impact of ICI use on post-LT outcomes in an individual patient data meta-analysis. Data were included for 91 eligible patients.

The researchers found that during a median follow-up of 690.0 days, there were 24, nine, and nine allograft rejections, HCC recurrences, and deaths, respectively. Associations with allograft rejection were seen for age (adjusted hazard ratio [aHR] per 10 years, 0.72) and ICI washout time (aHR per one week, 0.92). For patients with ≤20 percent probability of allograft rejection, the median washout period was 94 days. There was no difference in overall survival seen between cases with and without allograft rejection. Fewer median ICI cycles were seen for individuals with versus without HCC recurrence (4.0 versus 8.0). A lower proportion of patients were within Milan criteria post-ICI among those with versus without recurrence (16.7 versus 65.3 percent).

"We concluded that with a 90-day gap between the last dose of immunotherapy and liver transplant, the risk of organ rejection is no greater than if the patient had never received immunotherapy," senior author Ju Dong Yang, M.D., from Cedars-Sinai Medical Center in Los Angeles, said in a statement.

Several authors disclosed ties to the biopharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-08-17 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords